Legal & compliance AddThis Sharing ButtonsShare to LinkedInLinkedInShare to FacebookFacebookShare to TwitterTwitter Subscribe to the iGaming newsletter Topics: Legal & compliance Marketing & affiliates Sports betting Comcast-owned media giant Sky said that a 18.2% decrease in advertising revenue in the third quarter of this year was largely due to the whistle-to-whistle ban on gambling advertising in the UK and new gambling advertising restrictions in Italy.Advertising revenue fell from $545m (£424.5mm/€490.1m) in the third quarter of 2018 to $446m in the third quarter of 2019, the first quarter since the ban came into effect.In its quarterly report, Comcast said the decline “reflects an unfavorable impact from a change in legislation related to gambling advertisements in the UK and Italy, as well as overall market weakness.”The Industry Group for Responsible Gambling (IGRG) introduced the whistle-to-whistle ban in December 2018. Under the ban, no gambling advertising can now be shown on pre-watershed sports from five minutes before a sporting event begins until five minutes after the event finishes, with the exception of horse and greyhound racing.The UK whistle-to-whistle ban was introduced on 1 August 2018, meaning that Sky’s figures refer only to two months of activity since it came into effect. With football’s English Premier League only starting on 10 August, the ban may also have a larger effect on future quarters that include three full months of Premier League games.Italy, meanwhile, introduced a total ban on gambing advertising on 1 January. As well as television advertising, commercial communications such as product placement, the distribution of branded items (including competitions with branded products as prizes), advertorials and influencer marketing are all banned.Advertising as a whole made up only 9.8% of Sky’s revenue, while the difference between 2018 and 2019 third-quarter advertising revenue came to 2% of the company’s total revenue.Sky previously owned operator Sky Betting and Gaming, but sold the majority of the business to private equity group CVC in 2015 before the Stars Group purchased both CVC’s portion of the comapny and Sky’s remaining 20% in 2018. Gambling advertising bans hurt Sky TV ad revenue 25th October 2019 | By Daniel O’Boyle Email Address Comcast-owned media giant Sky said that a 18.2% decrease in advertising revenue in the third quarter of this year was largely due to the whistle-to-whistle ban on gambling advertising in the UK and new gambling advertising restrictions in Italy. Regions: Europe UK & Ireland Southern Europe Italy
CricketPakistan Super LeaguePakistan Super League 2021 Previous articleICC WTC Final: India and New Zealand announce 15-member squads; All you need to know ahead of the World Test Championship FinalNext articleBCCI ends Mumbai spinner Ankeet Chavan’s ban, allows him to play professional cricket Kunal DhyaniSports Tech enthusiast, he reports on Sports Tech industry and writes on sports products. North AmericaWillow TV Share on Facebook Tweet on Twitter WTC Final Day 2 Stumps: Brilliant Virat Kohli & Ajinkya Rahane saves the day for India as bad light stops play 33 overs early Cricket NZSky NZ PSL 2021 LIVE Streaming Online –Where can fans watch the live streaming of PSL 2021 PES vs KAR in India?The live streaming of the PSL 2021 in India will be available on SonyLiv.You can also catch the live updates on insidesport.co.Fans around the globe can also stream the PSL 2021 online through BSports Pakistan on YouTube. South Asia (excluding Pakistan)Sony Pictures Network PSL 2021 PES vs KAR LIVE Streaming Online-: Where to watch LIVE stream of Pakistan Super League CarribeanFlow Sports ENG W vs IND W Test: Sneh Rana, Shafali Verma shine as one-off Test ends in draw Sub-Saharan AfricaSuper Sports Virat Kohli completes 10 years in Test Cricket: 10 things you should know about India skipper- check out Cricket PSL 2021 when will PSL 2021 be held?PSL 2021 will take place in UAE from June 9, 2021.PSL 2021 when will PSL 2021 final be held?PSL 2021 will take place in UAE from June 24, 2021.PSL 2021 What Time PSL 2021 PES vs KAR Will begins? TimePSL 2021 PES vs KAR Will begin at 11:30 PM ISTWhat are the venues for PSL 2021 PES vs KAR? – VenuePSL 2021 PES vs KAR will be played at UAE MENA, Aus and Row*tapmad.com/psl6 Cricket RELATED ARTICLESMORE FROM AUTHOR UAEetisalat CricLife 2 channel no 788 Cricket WI vs SA 2nd Test Day 2 Stumps: West Indies bowled out for 149 runs in 1st innings, SA lead by 149 runs PakistanPTV Sports & Geo Super WTC final LIVE broadcast: ICC’s mega broadcast plan, India vs New Zealand live streaming starts today in 195 countries TAGSPES vs KAR LIVEPES vs KAR Live StreamingPeshawar Zalmi vs Karachi kingPeshawar Zalmi vs Karachi king Live SHARE Facebook Twitter PSL 2021 New schedule -PSL 2021 squads: United KingdomSky Sports PSL 2021, KAR beats QUE: Karachi Kings defeats Quetta Gladiators to keep playoffs berth alive Cricket PSL 2021 PES vs KAR LIVE: How to watch Peshawar Zalmi vs Karachi king in your country, IndiaQuetta GladiatorsHassan Khan, Arish Ali Khan, Mohammad Nawaz, Khurram Shehzad, Usman Shinwari, Sarfaraz Ahmed (c), Andre Russell, Anwar Ali, Jack Wildermuth, Faf du Plessis, Saim Ayub, Usman Khan, Abdul Nasir, Jake Weatherald, Zahid Mahmood, Zahir KhanALSO READ: ICC WTC Final: Virat Kohli and Co hit the nets for first group training session since quarantine; Check videoPeshawar ZalmiAmad Butt, Umaid Asif, Kamran Akmal, Wahab Riaz, David Miller, Muhammad Imran, Mohammad Irfan, Mujeeb Ur Rahman, Haider Ali, Sherfane Rutherford, Tom Kohler-Cadmore, Shoaib Malik, Ravi Bopara, Saqib Mahmood, Imam-ul-Haq, Ibrar Ahmed, Mohammad Amir Khan PSL 2021 PES vs KAR LIVE: How to watch Peshawar Zalmi vs Karachi king Live Streaming in your country, India, Follow Live update PSL 2021 PES vs KAR LIVE: How to watch Peshawar Zalmi vs Karachi king in your country, IndiaFor more sports news and PSL 2021 updates, follow us at insidesport.co Cricket by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeManly BandsShop the New MLB CollectionManly BandsIPL 2020: Bad news for Sunrisers Hyderabad’s Jonny BairstowIPL 2020 : Srikanth and fans slams MS Dhoni, says ‘wasted 15 Cr on Jadhav & Chawla’This will be the second time both teams will come face to face in this edition. The two teams met in a high-scoring thriller at National Stadium Karachi in which the Kings turned out victorious by 6 wickets after chasing down 189 runs target with three balls to spare. Something similar is expected to take place again when both teams will meet in Abu Dhabi tomorrow night.If we look at the points table, Peshawar Zalmi is sitting at third spot with four wins and four defeats in eight encounters while Karachi Kings are placed just below them with three wins and three defeats in six games played so far. Having played two games less, the Kings will be looking to clinch the third spot from Zalmi, making a double over them.PSL 2021 LIVE-Where will PSL 2021 PES vs KAR be broadcasted in India?Sony Sports to Broadcast Pakistan Super League (PSL) 2021 PES vs KAR in INDIA Taonga: The Island FarmThe Most Relaxing Farm Game of 2021. No InstallEnjoy farming, stock up and make friends. Taonga is a whole world full of adventure!Taonga: The Island Farm|SponsoredSponsoredManly BandsShop the New MLB CollectionManly Bands|SponsoredSponsoredSenior Living | Search AdsNew Senior Apartments Coming to Scottsdale (Take A Look at The Prices)Senior Living | Search Ads|SponsoredSponsoredFreight & Shipping Quotes | Search AdsResearch & Compare Freight & Shipping QuotesEnjoy Affordable Freight & Shipping Services With These Service ProvidersFreight & Shipping Quotes | Search Ads|SponsoredSponsoredYourBump15 Actors That Hollywood Banned For LifeYourBump|SponsoredSponsoredMoneyPailShe Was A Star, Now She Works In ScottsdaleNow she has a normal job.MoneyPail|SponsoredSponsored PSL 2021 PES vs KAR LIVE: How to watch Peshawar Zalmi vs Karachi king Live Streaming in your country, India, Follow Live update PSL 2021 PES vs KAR LIVE: How to watch Peshawar Zalmi vs Karachi king Live Streaming in your country, India, Follow Live update –The second match of Tuesday’s doubleheader in PSL 2021 will be played between Peshawar Zalmi and Karachi Kings at Sheikh Zayed Stadium, Abu Dhabi. ICC WTC Final, Ind vs NZ Day 3: Can India survive the Kyle Jamieson storm in Southampton? By Kunal Dhyani – June 15, 2021 Cricket PSL 2021 ISL beat MUL: Mohd Wasim Jr, Shadab Khan shine as Islamabad United defeats Multan Sultans by 4 wickets PSL Latest Points Table: Lahore Qalandars lose playoff berth, Islamabad United tops leaderboard PSL 2021 New schedule – PSL 2021 SCHEDULETuesday, June 15: Quetta Gladiators v Lahore Qalandars (5pm); Peshawar Zalmi v Karachi Kings (10pm)Wednesday, June 16: Multan Sultans v Quetta Gladiators (8pm)Thursday, June 17: Islamabad United v Peshawar Zalmi (5pm); Karachi Kings v Lahore Qalandars (10pm)Friday, June 18: Multan Sultans v Lahore Qalandars (8pm)Saturday, June 20: Quetta Gladiators v Karachi Kings (5pm); Multan Sultans v Islamabad United (10pm)Monday, June 21: Qualifier (1 v 2) (5pm), Eliminator 1 (3 v 4) (10pm)Tuesday, June 22: Eliminator 2 (loser Qualifier v winner Eliminator 1) (8pm)Thursday, June 24: Final (8pm)PSL 2021 Replacements: From Shimron Hetmyer to Johnson Charles; check full list of PSL 2021 replaced players Also, PCB has joined hands with Tapmad TV for streaming of the Pakistan Super League 6 matches in Australia, MENA (Middle East and North Africa) regions as well as the RoW* (Rest of the World) Cricket WTC Final LIVE: Virat Kohli becomes only player to play all major ICC finals PSL 2021 PES vs KAR LIVE: How to watch Peshawar Zalmi vs Karachi king in your country, IndiaPSL 2021 live streaming – PSL Live on Facebook: With Pakistan’s biggest cricketing event HBL Pakistan Super League (PSL) set to return on Wednesday, June 9, 2021, in Abu Dhabi, the Pakistan Cricket Board is collaborating with Facebook to bring the event to the global audience via the platform’s Paid Online Events. Read More: Cricket Cricket
ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/896163/campo-de-ourique-70-building-fragmentos-de-arquitectura Clipboard Year: Houses CopyAbout this officeFragmentosOfficeFollowProductsSteelConcrete#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousesLisbonPortugalPublished on June 15, 2018Cite: “Campo de Ourique 70 Building / Fragmentos” [Campo de Ourique 70 / Fragmentos] 15 Jun 2018. ArchDaily. Accessed 11 Jun 2021.
23 total views, 1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis IT security firm Security Partnerships has donated £25,000 of its consultancy services to the British Red Cross in a one-year cause related marketing (CRM) initiative.The agreement was completed very quickly: Security Partnerships’ staff were working for the Red Cross within three weeks of initial contact.The British Red Cross has 125 sites and 1,100 properties and its requirement for security is growing all the time, so the support from Security Partnerships (SP) should prove valuable. Advertisement About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving. Dan Harris, Director at Security Partnerships, said: “In our experience charitable organisations face the same IT security risks as corporate businesses but often lack the ability to attract quality suppliers who will work for discounted rates. The arrangement we have with the British Red Cross works well for both of us.”In addition to the free consultancy, SP will provide all products at cost price. AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis Howard Lake | 19 January 2005 | News IT security firm in CRM partnership with British Red Cross Tagged with: Technology Trading
United flight attendants demand unified contractUnited Airlines’ flight attendants may soon see across-the-board pay increases, some as high as 31 percent, pending ratification of the tentative contract between the company and the Association of Flight Attendants. The contract will finally unite the airline’s 25,000 flight attendants, who have remained under separate collective bargaining agreements since the 2010 merger of Continental Airlines and United. Under the current contract, flight attendants originally hired by Continental are barred from working alongside United hires. (New York Times, June 30)Workers from United, Continental and Continental Micronesia, the three pre-merger bargaining groups, have protested at airports around the world to demand a unified contract. A statement posted at the AFA website explains: “Management will have the opportunity to divide and distract us as long as we are operating under different agreements. They play games with flying allocation and attempt to keep us at odds with each other. A divided workforce gives management leverage they can and will use against us.” (OurContract.org, Feb. 9) The AFA bargaining committee, with representatives from each pre-merger group, has unanimously approved the tentative agreement. Members will vote to ratify it beginning July 15. (OurContract.org, June 29)Workers strike at Trump Taj MahalA thousand service workers, including housekeepers, kitchen staff and bellhops, walked off the job July 1 at Atlantic City’s Trump Taj Mahal hotel and casino. “We’ve given them every chance possible to do the right thing,” said Mayra Gonzales, a 26-year Taj chef. “Now we’re going to take it to the streets.” (unitehere.org, July 1)The workers, unionized by UNITE HERE Local 54, are fighting to recover wages and health care benefits cut by as much as 35 percent when the Taj Mahal declared bankruptcy in 2014. Billionaire Carl Icahn, the hotel and casino’s principal investor and owner as of February 2016, has raked in enormous profits from workers’ low-paid labor. Many are paid only 80 cents more an hour than when they started over a decade ago. (Trump founded the hotel in 1990, but later sold it to Icahn; Trump gets a percentage of the profits for the use of his name.)A report by corporate watchdog groups Hedge Clippers and Take on Wall Street says that Icahn’s investments in insurance, air travel and software industries have caused some 35,000 workers to lose their jobs and 126,000 to lose their pensions and health plans. It also notes that billionaire Donald Trump, the Republican presidential candidate, is considering Icahn for Treasury secretary, if elected. (Fortune.com, July 5)Home care workers make gainsThe Supreme Court confirmed on June 27 that millions of domestic care workers, the majority immigrants and women of color, are entitled to minimum wage and overtime protections when it declined to hear the case of Home Care Association of America v. Weil. The for-profit home care agencies sued the federal government to overturn a 2015 Labor Department rule that reclassifies home care workers as employees, rather than “companions” exempt from labor laws. (New York Times, July 3)The 1937 “Fair Labor Standards Act” granted most employees the right to a minimum wage and overtime pay. But racist Southern Democratic lawmakers successfully lobbied to exclude domestic workers and agricultural workers, mostly people of color, from the law’s scope. So millions of home care workers and farmworkers have had to work long hours at poverty wages ever since.In a July 8 editorial celebrating the decision, SEIU Healthcare Illinois, Indiana, Missouri, Kansas President Keith Kelleher wrote, “For nearly 80 years, women and men of color have been fighting against the injustice baked into our basic workplace rules — and we’re winning.” (ProgressIllinois.com)Workers’ global solidarity vs. WalmartSince 1996, U.S.-based retail giant Walmart has expanded operations in China, opening some 400 stores and employing over 100,000 workers. Like its U.S. counterpart, Walmart China does all it can to push down wages and increase productivity, even flagrantly violating China’s robust labor laws.In a May 20 open letter to U.S. Walmart workers, the Walmart Chinese Workers’ Association urges “further communication and mutual support between the Walmart workers in China and the U.S. in the future.” The association was formed in 2014 to connect Walmart workers across China as “Walmart flagrantly violated the trade union law of China and the five-point memorandum that was agreed to by Walmart and the ACFTU [Chinese labor federation] in 2006. Secondly, in its stores across the country, Walmart has conducted a series of actions to illegally manipulate union elections, suppress trade union activists, and appoint fake representatives for union negotiations.” The letter notes that Walmart workers’ struggles in the U.S. to unionize and demand regular scheduling are not unique to them. “We … believe that your conditions today will be ours tomorrow.” International solidarity against Walmart is the key to victory in both countries. To read the full letter, go to bit.ly/29sHnxG.FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare this
Facebook Benton McDonaldhttps://www.tcu360.com/author/benton-mcdonald/ Kianna Ray finished with 10 points and 4 assists Sunday. Photo by Porter Burns Facebook Settlement reached between TCU, former professor in discrimination lawsuit Benton McDonaldhttps://www.tcu360.com/author/benton-mcdonald/ Linkedin ReddIt ReddIt Thousands of TCU community members receive COVID-19 vaccines as university supply increases Benton McDonald is a senior journalism and political science double major from Austin, Texas. He has worked for TCU360 since his freshman year and is currently the executive editor. Benton McDonaldhttps://www.tcu360.com/author/benton-mcdonald/ Board approves tuition freeze, RRI actions but doesn’t act on eligibility issue spurred by Williams TCU baseball finds their biggest fan just by saying hello Benton McDonald Chancellor talks stimulus money, COVID-19 vaccines and more at limited attendance faculty town hall Previous articleHoroscope: January 28, 2019Next articleWomen’s tennis remains undefeated with win over Lamar Benton McDonald RELATED ARTICLESMORE FROM AUTHOR + posts Twitter Linkedin Another series win lands TCU Baseball in the top 5, earns Sikes conference award Benton McDonaldhttps://www.tcu360.com/author/benton-mcdonald/ TCU rowing program strengthens after facing COVID-19 setbacks Twitter printKianna Ray finished with 10 points and four assists Sunday. Photo by Porter BurnsThe best teams find their best players when they need them the most. Facing a storming Kansas team who ended the third quarter on an 11-0 run and trailed by just three, TCU turned to senior Jordan Moore who reeled off the Horned Frogs first eight points of the fourth quarter, out-scoring the Jayhawks by six during that stretch. Moore’s eight along with four straight free throws by Amy Okonkwo down the stretch would give the Horned Frogs a 58-53 victory Sunday.Moore’s play on both ends was pivotal to the team’s victory. Photo by Porter BurnsIt was the lowest points the team has scored in a victory all season, highlighting what head coach Raegan Pebley called an “uncharacteristic” offensive performance. The Horned Frogs shot 42.2 percent from the field and made just two of their three-pointers. More complicit in their offensive woes was the season-high 26 turnovers they committed, including 18 in the second half. “That’s uncharacteristic of us but I know its characteristic of Kansas’s defense,” said Pebley. “We just didn’t have great flow.”Lacking the offensive execution that usually guides them to victories, the team leaned on experience and size to hold off the Jayhawks late. Moore would finish with 22 points and 10 rebounds, her third consecutive game with 20 points and second straight double-double. “I wouldn’t really say its a zone,” Moore said of her recent performances. “I just do what I’m supposed to do. I’m supposed to get rebounds, I’m supposed to score, I’m supposed to be where my teammates need me to be at all times and that’s what I did tonight.”Eight of her 22 points came at the line, indicative of the Horned Frogs emphasis on getting the ball inside and drawing whistles.Forty-seven of the team’s 58 points came from either inside the paint or at the free-throw line, a commitment to the game plan that resulted in the win.The team scored 30 points from the paint Sunday, part of their gameplan to attack the Jayhawk defense. Photo by Porter Burns“We did feel like we could look at some penetration and there were some seams we could try and expose and attack,” Pebley said. Along with Moore’s fourth quarter offense, the team relied on a defense that attacked the ball all game long. Jayde Woods led the way with four steals, including one off of a Kansas inbounds pass with 12 seconds left that gave TCU the ball back with just a one-point lead. The Jayhawks would foul Okonkwo after the steal, allowing her to go to the line and sink two free throws to push the lead to three. Okonkwo would return to the line and effectively end the game with two more free throws after another Kansas turnover with 10 seconds remaining. The offense of Moore, defense of Woods and composure of Okonkwo all culminated in a gritty win that younger, more inexperienced Horned Frog teams may not have been able to pull off. “Experience helps you so much in this conference,” Pebley said. “In the past, we’ve been one of the more youthful teams and I think their experience, as well as players like Kianna [Ray], has just helped us so much.” The team will look to build on the confidence that comes with closing out a tight game as they head into the final stretch of their season. With 10 games remaining, they stand at 14-5 overall with a 4-4 record in the Big 12.They will get the chance to get over the .500 hump in conference play against Kansas State at 6:30 p.m. on Wednesday, Jan. 30 in Manhattan, Kansas.
People Altadena Chamber Names Monica Hubbard, El Patron as Altadena’s Best for 2014 Chamber of Commerce names the community activist and the popular restaurant as Citizen and Business of the Year From STAFF REPORTS Published on Tuesday, January 27, 2015 | 3:30 pm Name (required) Mail (required) (not be published) Website Business News Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadena 4 recommended0 commentsShareShareTweetSharePin it Your email address will not be published. Required fields are marked * Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday Community News HerbeautyRed Meat Is Dangerous And Here Is The ProofHerbeautyHerbeautyHerbeautyThese Are 15 Great Style Tips From Asian WomenHerbeautyHerbeautyHerbeauty10 Questions To Start Conversation Way Better Than ‘How U Doing?’HerbeautyHerbeautyHerbeauty7 Most Startling Movie Moments We Didn’t Realize Were InsensitiveHerbeautyHerbeautyHerbeautyA Mental Health Chatbot Which Helps People With DepressionHerbeautyHerbeautyHerbeauty6 Strong Female TV Characters Who Deserve To Have A SpinoffHerbeautyHerbeauty Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS Community News Make a comment faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Virtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyCitizen Service CenterPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes Top of the News More Cool Stuff First Heatwave Expected Next Week Altadena’s citizen Of the Year Monica Hubbard, and Business Of The Year, El Patron, Owner Alex CortexThe Altadena Chamber of Commerce has named local activist Monica Hubbard as its 2014 Citizen of the Year. El Patron Mexican Restaurant, a popular eatery with two locations, was named 2014 Business of the Year.Citizen of the Year Monica HubbardMonica Hubbard has spent her career putting disparate things together to make a greater whole. From 1966 through 1999 she conducted choirs in academic, church and community settings. When Caltech first admitted women undergraduates, she taught voice and conductedÂ choirs there from 1972-1999, as well as conducting choirs for public and private schools. She was the national repertoire and standards chair for the American Chorale Directors Association and was instrumental in getting ACDA to have a national womenâ€™s honor choir perform at a national convention, as well as working to develop and commission new choral works. She also started the first database of repertoire composed specifically for womenâ€™s voices, and repertoire for upper voices by women composers.After 27 years at Caltech, she left conducting to open a consulting practice for arts and social services nonprofits with a focus on board development and capacity-building. Her clients have included the Pasadena Playhouse, Los Angeles County Arts Commission, the AIDS Service Center, and Occidental College. Her foremost tool has been her computer: â€œCaltech gave me my very first computer,â€ she said, and she quickly mastered its possibilities in terms of research, communication, and creating databases, and carried this into her consulting work. Along the way, she created â€œWired Women,â€ a weekly email newsletter that covered womenâ€™s issues and events in the greater Pasadena area.But as an Altadena resident, she said she also wanted to connect â€œthe people who were doing positive thingsâ€ closer to home, and created a second newsletter, the â€œAltadena Womenâ€™s Network.â€ She also began to work more closely with and cultivated relationships in the Altadena community, serving as a neighborhood watch co-captain, joining the Sheriffâ€™s Community Advisory Committee and serving on the town councilâ€™s Public Education Committee. She is a member of multiple community groups, including Altadena Heritage, the Altadena Historical Society, and Friends of the Altadena Libraries, among many others. She is a founding member and/or board member of Invest in PUSD Kids, Pasadena Village, and the Pasadena Educational Foundation. She was also a member of the Altadena Chamber of Commerce Board of Directors from 2007-2009.More recently, she has been involved in founding two organizations: the Altadena Library Alliance, which recently succeeded in passing Measure A, assuring funding of the Altadena Library District through a special parcel tax for the next ten years; and Neighbors Building a Better Altadena. A group that was started to raise concerns about a Walmart Neighborhood Market opening in Altadena, NBBA is now working on making Altadenaâ€™s business districts more â€œwalkableâ€ and art-filled. NBBA models working with other organizations, such as the Altadena Town Council and Chamber of Commerce, to cooperatively make concrete things happen toÂ improve the community.â€œI really like connecting people with resources,â€ Hubbard said. â€œWhen I see people do good, I like to help them in any way possible.”As for being named Citizen of the Year, â€œIâ€™m surprised and delighted,â€ Hubbard said. â€œItâ€™s an honor. When I look at some of the people who received it in the past, itâ€™s a little humbling.â€Business of the Year: El Patron Mexican RestaurantFor a relatively new business — it will be five years old in May — El Patron Mexican Restaurant has already made a big splash in Altadena. Not only has it gotten a reputation for good, hearty food and excellent service — and has opened a second location — but you can count on the restaurant helping out at local events, fundraisers, and other gatherings, giving back to theÂ community that brought it success.All this in a location that has seen many restaurants come and go over the years. El Patron is here to stay.Owner-founder Alex Cortes comes from a family in the restaurant business, and always wanted to have a restaurant of his own. He was working for an Irwindale-based candy distributor ten years ago when he opened his first restaurant with his brother at an Irwindale location. They sold that business after a year, and Cortes continued working for the candy distributor. When his employer announced it was moving to El Segundo, farther from home, Cortes began looking for another opportunity to open his own restaurant. An amateur boxer, Cortes said that he went to his gym one evening, found it closed, and decided to drive around a bit in the late night. In Altadena, he came across a â€œFor Rentâ€ sign at a wedge-shaped Googie-style building almost on the corner of Lake Avenue and Altadena Drive, a site where many restaurants were born and died over the years.He called the landlord, took a tour of the building, and decided it was what he was looking for. While he and his wife Margarita had saved money for a down-payment on a home, she encouraged him to invest their money in the restaurant he always wanted.Â Cortes said that, when the landlord called to offer him the building, they were in the hospital, with Margarita in labor. That day, his son was born, and the next day, he had a restaurant.Cortes started out with just basic restaurant equipment and skeleton crew, but â€œthe community gave us a good welcome,â€ he said. The restaurantâ€™s kitchen is still being upgraded and improved, but the business was good enough that â€œmost of my family works here,â€ Cortes said — including two brothers and two sisters.While the original location at 2555 N. Lake Avenue is a full sit-down restaurant, they opened another location at Lincoln Crossing, 2234 Lincoln Avenue, that emphasizes take-out Mexican food. El Patron has also branched out to help the community in many ways. Once a month, the restaurant holds a fundraiser where 15 percent of the proceeds go to a local organization.Beneficiaries have included the Altadena Relay for Life, the Altadena Library Alliance, and the St. Markâ€™s Church Haiti fund.El Patronâ€™s pop-up tent also shows up at community events, including the Farnsworth Park summer concert series, the Altadena Community Center 10th Anniversary Celebration, the North Lake Pole Holiday Festival and Sidewalk Sale, and it has been part of last yearâ€™s â€œTaste of Altadenaâ€ at the Chamber of Commerce annual meeting.â€œI feel good — itâ€™s exciting,â€ Cortes said about the Chamberâ€™s honor. â€œI wasnâ€™t expecting to be Business of the Year. Itâ€™s an accomplishment for me and my team.â€El Patron Mexican Restaurant and Monica Hubbard will be honored at the Altadena Chamberâ€™s installation of officers and â€œTaste of Altadenaâ€ dinner at the Altadena Town & Country Club on Feb. 6, 2015. Subscribe
NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Feb 25, 2021– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the opportunity to receive a 30 µg booster of the current vaccine 6 to 12 months after receiving their initial two-dose regimen. The study is part of the Companies’ clinical development strategy to determine the effectiveness of a third dose against evolving variants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005515/en/ Separately, in order to be prepared for any potential future strain changes, Pfizer and BioNTech are in ongoing discussions with regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, regarding a registration-enabling clinical study to evaluate a variant-specific vaccine having a modified mRNA sequence. This study would use a new construct of the Pfizer-BioNTech vaccine based on the B.1.351 lineage, first identified in South Africa. This could position the Companies to update the current vaccine quickly if the need arises to protect against COVID-19 from circulating strains. In alignment with the updated guidance issued by the FDA regarding emergency use of vaccines to prevent COVID-19 which provides recommendations for evaluating a modified vaccine to address variants, the Companies are hoping to pursue the validation of future modified mRNA vaccines with a regulatory pathway similar to what is currently in place for flu vaccines. “While we have not seen any evidence that the circulating variants result in a loss of protection provided by our vaccine, we are taking multiple steps to act decisively and be ready in case a strain becomes resistant to the protection afforded by the vaccine. This booster study is critical to understanding the safety of a third dose and immunity against circulating strains,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “At the same time, we are making the right investments and engaging in the appropriate conversations with regulators to help position us to potentially develop and seek authorization for an updated mRNA vaccine or booster if needed.” “Our proactive clinical development strategy aims to create the foundation today, that will enable us to address the challenges of tomorrow. We want to be prepared for different scenarios,” said Ugur Sahin, CEO and Co-founder of BioNTech. “Therefore, we will be evaluating a second booster in the current regimen as well as preparing for a potential rapid adaption of the vaccine to address new variants which might escape the current version of our mRNA-based vaccine. The flexibility of our proprietary mRNA vaccine platform allows us to technically develop booster vaccines within weeks, if needed. This regulatory pathway is already established for other infectious diseases like influenza. We take these steps in order to ensure a long-term immunity against the virus and its variants.” Administering a third dose will provide an early assessment of the safety of a third dose of BNT162b2, as well as its immunogenicity. This study will evaluate up to 144 Phase 1 participants in two age cohorts, 18-55 and 65-85 years of age. The study will include trial participants who received the two doses in the Phase 1 study 6 to 12 months ago in order to assess the boostability of BNT162b2. Thus, the study will evaluate the safety and tolerability of a third vaccination irrespective of the level of antibody titers of the trial participant. Participants will be assessed at the time they receive the third dose, then one week and one month after, and Pfizer and BioNTech plan to study the ability of the sera from those participants to neutralize SARS-CoV-2 strains of interest. The participants will continue being followed in the study for up to 2 years as originally planned. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine.com. The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorizations Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries. AUTHORIZED USE IN THE U.S.: The Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. IMPORTANT SAFETY INFORMATION FROM U.S. FDA EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION:Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 VaccineAppropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 VaccineMonitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines ( https://www.cdc.gov/vaccines/covid-19/ )Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 VaccineThe Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipientsIn clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%)Severe allergic reactions, including anaphylaxis, have been reported following the Pfizer-BioNTech COVID-19 Vaccine during mass vaccination outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 VaccineAvailable data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancyData are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretionThere are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination seriesVaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. The reports should include the words “Pfizer-BioNTech COVID-19 Vaccine EUA” in the description section of the reportVaccination providers should review the Fact Sheet for Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use AuthorizationPlease see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine-us.com About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Pfizer Disclosure Notice The information contained in this release is as of February 25, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program, the mRNA platform and regulatory pathway and the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) (including qualitative assessments of available data, potential benefits, a potential booster dose and a potential new variant-specific vaccine, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the in vitro and Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations upon commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when a Biologics License Application for BNT162b2 may be filed in the U.S. and whether and when other biologics license and/or emergency use authorization applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including a potential Biologics License Application in the U.S.) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. About BioNTech Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de. BioNTech Forward-looking Statements This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential second booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law. View source version on businesswire.com:https://www.businesswire.com/news/home/20210225005515/en/ CONTACT: Pfizer: Media Relations Jerica Pitts +1 (347) 224-9084 [email protected] Investor Relations Chuck Triano +1 (212) 733-3901 [email protected] BioNTech: Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 [email protected] Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 [email protected] KEYWORD: NEW YORK GERMANY EUROPE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH PHARMACEUTICAL CLINICAL TRIALS SOURCE: Pfizer Inc. Copyright Business Wire 2021. PUB: 02/25/2021 06:45 AM/DISC: 02/25/2021 06:45 AM http://www.businesswire.com/news/home/20210225005515/en Facebook Facebook WhatsApp Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants Pinterest WhatsApp Pinterest TAGS By Digital AIM Web Support – February 25, 2021 Local NewsBusiness Twitter Twitter Previous articleMerck to Acquire Pandion TherapeuticsNext articleGenalyte and Sonora Quest Laboratories Partner to Provide Predictive Analytics for Cigna’s Medicare Advantage Plan Digital AIM Web Support
iStock/Thinkstock(PHOENIX) — Two pilots on different aircraft reported having close encounters with a mysterious object flying high above Arizona last month, according to the Federal Aviation Administration.The sightings occurred within minutes of each other on the afternoon of Feb. 24, some 40,000 feet above southern Arizona near the New Mexico border. ABC News obtained the audio recording of the conversation between the pilots and the Albuquerque Air Route Traffic Control Center, released by the FAA.The news comes amid a series of reports of military pilots coming into contact with what they believed to be UFOs and the disclosure of a secret, but now-defunct Pentagon program to track such incidents.The pilot of a Learjet 36 belonging to Phoenix Air, with the tail number N71PG, reported the initial sighting. He asks the controller: “Was anybody above us that passed us like 30 seconds ago?“Negative,” the controller responds.“OK. Something did,” the Learjet pilot says.“It’s a UFO,” another pilot chimes in.“Yeah,” the Learjet pilot laughs.A few minutes later, the controller radios to American Airlines Flight 1095, an Airbus A321. He asks the pilot, “Let me know if you see anything pass over you here in the next 15 miles.”The pilot seems puzzled and responds, “If anything passes over us?”“Affirmative. We had an aircraft in front of you at 37 [thousand feet] that reported something pass over him and we didn’t have any [radar] targets, so just let me know if you see anything pass over you,” the controller says.“All right,” the pilot says.The Learjet pilot joins the conversation, saying, “I don’t know what it was, it wasn’t an airplane but it was — the path was going in the opposite direction.”About a minute later, the American Airlines Flight 1095 pilot radios back to the controller to report a bizarre sighting in Arizona’s airspace.“Yeah, something just passed over us, like a — I don’t know what it was. But it was at least two, three thousand feet above us. Yeah, it passed right over the top of us,” the pilot says.“OK, American 1095, thank you,” the controller responds.The controller later asks, “American 1095, can you tell if it was in motion or just hovering?”“Couldn’t make it out whether it was a balloon or whatnot. But it was just really beaming light or could have had a big reflection and was several thousand feet above us going opposite direction,” the pilot says.“Roger,” the controller responds.The American Airlines pilot later radios to the controller again, asking if the unidentified object was a “Google balloon.”“Doubtful,” the Learjet pilot chimes in.The voice of another pilot adds, “UFO.”The controller was unable to verify that any other aircraft was in the area at the time of the reported sightings, according to a spokesperson for the FAA.“We have a close working relationship with a number of other agencies and safely handle military aircraft and civilian aircraft of all types in that area every day, including high-altitude weather balloons,” the spokesperson told ABC News in an email Wednesday.Copyright © 2018, ABC Radio. All rights reserved.